Kodiak's Zenkuda and tabirafusp-ted hit primary endpoints in Phase 3 DAYBREAK trialSep 28Clinical readoutKodiak Sciences Inc
Ollin Biosciences registers two Phase 3 trials of OLN324 for diabetic macular edemaSep 25Weekly roundup, 2 itemsOllin Biosciences, Inc
Regeneron's EYLEA HD posts Phase 3b safety results; dupilumab keloid study completesSep 18Weekly roundup, 2 itemsafliberceptdupilumab
4DMT reports Q2 2026 results, completes enrollment for second wet AMD Phase 3 trialAug 13Quarterly update4D Molecular Therapeutics
Kodiak reports Q2 2026 results, confirms three Phase 3 readouts by year-endAug 13Quarterly updateKodiak Sciences Inc
Ocular Therapeutix targets Q4 2026 AXPAXLI NDA filing for wet AMD after FDA meetingAug 3Quarterly updateOcular Therapeutix, Inc.
Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial missesJul 30Quarterly updatecemdisiranfianlimab
Kodiak Sciences recruiting Phase 3 ALTO trial testing tabirafusp tedromer vs. aflibercept in DMEJul 29Trial updateafliberceptKodiak Sciences Inc
Merck registers Phase 2 MK-1045 trial in B-cell cancers; letermovir CMV study also listedJul 16Weekly roundup, 4 itemsafliberceptletermovir
Sign inSign in